24 okt: Novozymes overvejer at appellere tabt patentsag i USA
24 okt: Novo-rival overrasker positivt - diabetesmidler præsterer godt - ..
24-10-2017 12:43:07

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

Relateret indhold
28 maj - 
Zealand Pharma afslutter fase 3-studie - resultater lan..
16 maj - 
Zealand Pharma Q1: Øger underskud - færre royalty-indtæ..
26 apr - 
Zealand Pharma får grønt lys til afgørende studie med t..
Relateret debat
07:54 - 
Til dine links er der kun at sige: Alt går i ZP's retni..
07:50 - 
Come on, det er to helt forskellige produkter. MiniMed ..
17 jun - 
"Artificial pancreas treatment improves glycaemic contr..

Company announcement - No. 48/2017

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS)*. Glepaglutide is a Zealand-invented long-acting GLP-2 analog that may offer a treatment option for patients with reduced or complete loss of intestinal function. Glepaglutide has been shown to reduce fecal wet weight output as well as indicated increases in both energy, fluid and electrolyte absorption in SBS patients in a Phase 2 trial. Interactions with U.S. and EU regulatory authorities are planned with the aim of moving glepaglutide into Phase 3 clinical trials in 2018.

Britt Meelby Jensen, President and CEO of Zealand, comments:

"The orphan drug designation is great news, both for Zealand and for the patients suffering from short bowel syndrome. The orphan drug designation for glepaglutide enables us to have a closer and more frequent dialogue with the FDA throughout our late stage clinical development. Glepaglutide is one of Zealand's leading product candidates, which we are developing all the way to market, and this designation is an important step for us in our efforts to ensure an efficient path to registration and patient access."

The United States Congress passed the Orphan Drug Act in 1983 to provide incentives for industry investment in treatments for rare conditions. Companies that receive orphan drug designation for their products qualify for various incentives including tax credits for clinical trial costs, relief from prescription drug user fees and the potential for seven years of market exclusivity after the drug is approved.

Short bowel syndrome

Short bowel syndrome (SBS) is a life-threatening and complex chronic severe condition associated with reduced or complete loss of intestinal function. In adults, the main underlying causes of SBS are major intestinal surgery following Crohn's disease, ischemia, radiation damage and surgery. It is estimated that 20,000-40,000 patients are affected by SBS in the U.S. and Europe. The most severely affected people are dependent on daily parenteral support. This requires them to be connected to infusion lines and pumps, which pose significant restrictions on their ability to engage in daily activities.

For further information, please contact:

Britt Meelby Jensen, President and CEO

Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim as well as a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow us on Twitter @ZealandPharma or LinkedIn.

*https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?

cfgridkey=539216 

48-17_1024 Orphan drug designation US glepaglutide


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 821615.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
17 jun
ZEAL
Zealand Pharma er investorer i Beta Bionics.   Beta Bionics har indgået e aftale med Senseonics, hvi..
6
13 jun
ZEAL
Nu skal jeg selvfølgelig ikke uden videre forklejne 7 skamfulde år i den stråtækte, men Billion bety..
4
17 jun
ZEAL
Bare ikke kursen :o
3
13 jun
ZEAL
IPO'en var også oplyst tidligere, da fase 3 var succesfuldt og NDA sker i Q3-2018 og godkendelse for..
3
11 jun
ZEAL
Har du nogensinde fremlagt positive fakta om noget som helst fra Zealand Pharma ? Lever du ikke kun ..
3
13 jun
ZEAL
Blandt så meget andet storskrydende sludder har du ved flere lejligheder hævdet, at du i dit arbejds..
2
13 jun
ZEAL
Som selvudråbt tidl. revisor og ditto bankdirektør burde du ærligt talt kunne kende rimelig forskel ..
2
13 jun
ZEAL
Det kan i hvert fald undre, at man slår så store brød op allevegne, når nu bukserne så tydeligvis ik..
2
13 jun
ZEAL
Det betyder vel først og fremmest, at der en selvudnævnt revisor-spire, der skal have refunderet de ..
2
13 jun
ZEAL
Så Xeris Pharmaceuticals har også set forkert på markedet for en rescue pen ? Hvor mange hospitals i..
2

Aktier/tendens: Nye C25-medlemmer, DSV og Vestas i fokus

18-06-2018 08:36:55
Tre nye selskaber indtræder mandag i det danske eliteindeks C25, hvor der også vil komme fokus på DSV efter en sænket analytikeranbefaling og Vestas efter en stor amerikansk ordre. Umiddelbart peger det i retning af en negativ aktieåbning i Europa, hvor den tyske DAX-future ligger 0,5 pct. lavere efter fald i de amerikanske aktiefutures og en generel sur stemning på de asiatiske børser. Det er for..

Spar Nord optager lån på 400 mio. kr.

15-06-2018 13:48:15
Spar Nord vil i næste uge optage et lån på 400 mio. kr., der har status af supplerende kapital. Et mindre antal professionelle investorer har lånt banken pengene. Lånet har en løbetid på ti år, men der er mulighed for at betale det ud efter fem år. De første fem år er renten på 2,53 pct., og udstedelsen vil gælde fra 19. juni, oplyser Spar Nord i en meddelelse til fondsbørsen. Supplerende kapital ..

Mærsk: Fragtraterne falder for anden uge i træk

15-06-2018 09:23:33
Spotpriserne på containerfragt faldt 3,5 pct. til 777,70 i denne uge ifølge rateindekset Shanghai Containerized Freight Index (SCFI). Dermed fortsætter sidste uges fald, efter at priserne ellers var steget de to foregående uger.Indekset har bevæget sig en del, siden det var nede at vende i årets bund i 568,68 i slutningen af marts.SCFI-indekset sammensættes på baggrund af spotprisen på fragt fra S..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Nye C25-medlemmer, DSV og Vestas i fokus
2
KORR: Vestas: Modtager storordre på 442 MW i USA - GENT
3
DSV/Morningstar: Sænker anbefalingen til "sælg"
4
Vestas/Sydbank: Regner med stærk afslutning på andet kvartal
5
Mærsk/Clarksons: Skærer 20 pct af kursmålet - GENT

Relaterede aktiekurser

Zealand Pharma A/S 95,20 -0,7% Fald i aktiekurs
Zealand Pharma Aktiesels.. 95,90 -0,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juni 2018 09:57:14
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180613.1 - EUROWEB5 - 2018-06-18 09:57:14 - 2018-06-18 09:57:14 - 1 - Website: OKAY